INNOVADERM-RESEARCH
21.7.2022 17:02:12 CEST | Business Wire | Press release
Innovaderm’s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences’ VTAMA® (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults.
Discovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin condition that causes itchy, scaly patches on different parts of the body and has a significant detrimental effect on quality of life.
“This is a great milestone for patients – one that we have been working towards for years,” says Dr. Robert Bissonnette, Innovaderm’s founder and CEO. “Innovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis. We not only played an instrumental role through our participation in multicenter phase 2 and 3 studies, but we were also the first to demonstrate tapinarof’s efficacy in proof-of-concept studies in both psoriasis and atopic dermatitis.”
VTAMA® cream is a once-daily, topical medication for psoriasis. Currently, clinical trials are underway to study this medication among patients with atopic dermatitis.
“VTAMA® cream is a non-steroidal topical that is a new chemical entity and the first-in-class therapy to be approved in the topical psoriasis space in 25 years,” says Anna Tallman, PharmaD, Vice-President of Medical Affairs at Dermavant Sciences. “We appreciate the collaboration and partnership with Dr. Bissonnette and Innovaderm to help bring forward an effective new treatment option in the United States that has the potential to benefit adults with plaque psoriasis across the entire disease severity spectrum – from mild to severe.”
Dr. Bissonnette and Tallman recently contributed to an article on the phase 3 tapinarof studies, which was published in the New England Journal of Medicine. To learn more: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2103629
For information on Innovaderm’s early to late phase study capabilities, visit our website .
IMPORTANT SAFETY INFORMATION
Indication : VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist approved in the US for the topical treatment of plaque psoriasis in adults. Adverse Events : The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.
See full Prescribing Information and Patient Information .
Innovaderm Research Inc.
Innovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.
Dermavant Sciences
Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company’s medical dermatology pipeline includes both approved and late-stage development product candidates the company believes may address important immuno-dermatological conditions, including plaque psoriasis and atopic dermatitis. For more information, please visit www.dermavant.com , and follow us on Twitter (@dermavant ) and LinkedIn (Dermavant Sciences ).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005175/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Suzano Reports Record Sales and Continued Improvements in Operational Efficiency in 202511.2.2026 00:44:00 CET | Press release
Suzano, the world’s largest pulp producer, announces its results for both the final quarter (4Q25) and the full year (2025), reporting record annual sales volumes and net revenue. The company also reported an improvement in its cash cost of pulp production, reflecting the drive for improved operational efficiency. Pulp and paper sales reached 14.2 million tonnes, a 15% increase compared to 2024. This performance was driven primarily by the strong operational contribution of the Ribas do Rio Pardo pulp mill, which began production in July 2024, and the company’s paper mills in the United States. As a result, Suzano’s full‑year net revenue reached a record R$50 billion in 2025. The company’s consistent focus on efficiency and cost discipline also contributed to a meaningful reduction in the cash cost of pulp production. Excluding downtime, the annual cash cost was R$817 per tonne, reaching its lowest annual level since 2021. Operational efficiency also helped Suzano deliver operating cas
Eclipse Signs Partnership Agreement With BNP Paribas to Power the Next Stage of Growth11.2.2026 00:05:00 CET | Press release
The agreement includes a strategic equity investment in Eclipse by BNP Paribas Eclipse, a leading battery storage, development, and energy trading company, and BNP Paribas, one of the largest banks in the Eurozone, today announced a strategic partnership to accelerate the deployment of Battery Energy Storage Systems (BESS) and strengthen Europe's energy resilience. This partnership includes a strategic equity investment in Eclipse by BNP Paribas. Through its proprietary algo trading software, Flowstream, Eclipse optimizes battery energy storage assets in real-time for its own and third-party assets. As an integrated BESS player, Eclipse develops, owns, and operates industrial-scale energy assets. The company currently has a pipeline of 16 projects in France and Belgium, representing a total capacity of 850 MW. The partnership with BNP Paribas provides asset owners with tailored financing solutions for BESS projects, as well as hedging instruments to manage merchant risk and reduce asse
World Governments Summit 2027 Date Announced, Following Largest-Ever Global Participation10.2.2026 22:06:00 CET | Press release
Largest edition in the summit’s history convened 6,250+ global leaders, policymakers, and experts from 150+ countriesWorld leaders, including presidents from Switzerland, Sierra Leone, and beyond, lead strategic dialogues Under the leadership of UAE President His Highness Sheikh Mohamed bin Zayed Al Nahyan and His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the World Governments Summit concluded in Dubai with its largest-ever participation, featuring more than 6,250 attendees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210283291/en/ World Governments Summit 2026 concludes in Dubai with record participation, bringing together more than 6,250 global leaders from over 150 countries to advance dialogue on governance, innovation, and sustainable development (Photo: AETOSWire) A Global Platform Convening Global Leaders Held in Dubai from 3 to 5 February, t
Palantir and Airbus Extend Strategic Collaboration10.2.2026 22:01:00 CET | Press release
Palantir Technologies (NASDAQ:PLTR) is proud to announce the extension of its collaboration with Airbus through a multi-year agreement, confirming a relationship that has driven innovation across the aerospace industry for over a decade. Under this renewed contract, Airbus will continue to rely on Palantir for Skywise, its civil aviation open data platform. The Skywise platform enhances aircraft and equipment designs and enables greater efficiency, safety and sustainability in the production of civil aircraft across the Airbus industrial footprint. It also improves the performance of airlines’ operations by combining in-flight engineering and operational data in an analytic rich environment enabling airlines to address their main challenges. This renewed commitment comes at a pivotal time, as the aerospace sector faces demands for innovation, agility, and competitiveness. With this renewed collaboration, Palantir will provide Airbus and its customers with continued access to cutting-ed
Grand Prix ACF AutoTech 2026 Unveils Its Six Finalist Startups10.2.2026 19:31:00 CET | Press release
The jury of the Grand Prix ACF AutoTech 2026, which met on February 9 at the Automobile Club de France, has selected six finalist startups following several hours of deliberation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210456562/en/ Jury members The selected companies stand out for their technological ambition, economic viability and tangible impact on automotive cost reduction and industrial performance. Key themes this year include AI-assisted engineering design, strategic independence from critical materials, and advanced LiDAR optimization. Finalist startups include: Grand Prix ACF (Mature startups) - Altrove (Paris, France): Develops innovative alternatives to high-risk critical inorganic materials using a proprietary algorithmic approach and unique artificial intelligence, strengthening industrial resilience and technological sovereignty. - Cognitive Design Systems (Toulouse, France): Provides an AI-powered
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom